Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nippon Shinyaku CoTSE:4516 +0.75%79 EV-to-EBIT is 4.43 as of Aug. 15, 2026, which is 73% below its 10-year median of 16.42. GuruFocus rates TSE:4516 with a GF Score™ of 79/100 and a GF Value™ of 円4,634.01 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 682 Drug Manufacturers companies, Nippon Shinyaku Co ranks better than 91.79% on this metric.
Nippon Shinyaku Co (TSE:4516) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nippon Shinyaku Co's Enterprise Value for the quarter that ended in Jun. 2026 was 円198,434 Mil.
Nippon Shinyaku Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円39,078 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nippon Shinyaku Co EV-to-EBIT Related Terms
Nippon Shinyaku Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Nippon Shinyaku Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nippon Shinyaku Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nippon Shinyaku Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nippon Shinyaku Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nippon Shinyaku Co's EV-to-EBIT falls into.
Nippon Shinyaku Co's current Enterprise Value is 円173,091 Mil.
Nippon Shinyaku Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円39,078 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nippon Shinyaku Co (TSE:4516) has a EV-to-EBIT of 4.43 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nippon Shinyaku Co and its competitors. This is 73% below median its historical median of 16.42. Over the past decade, Nippon Shinyaku Co's EV-to-EBIT has ranged from 3.97 to 42.01. According to the industry distribution chart, Nippon Shinyaku Co ranks #56 out of 682 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Nippon Shinyaku Co's EV-to-EBIT too high?
Nippon Shinyaku Co's current EV-to-EBIT of 4.43 is 73% below median its 10-year median of 16.42. Over the past 10 years, this metric has ranged from a low of 3.97 to a high of 42.01. The Drug Manufacturers industry median EV-to-EBIT is 15.86. Nippon Shinyaku Co's value of 4.43 is 72.1% below this industry median. Based on the distribution chart, Nippon Shinyaku Co ranks #56 out of 682 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Nippon Shinyaku Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nippon Shinyaku Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nippon Shinyaku Co ranks #56 out of 682 companies for EV-to-EBIT. This places Nippon Shinyaku Co in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.86. Nippon Shinyaku Co's value of 4.43 is 72.1% below this benchmark. Historically, Nippon Shinyaku Co's own EV-to-EBIT has ranged from 3.97 to 42.01 over the past decade. While the company's 10-year median is 16.42 vs. the industry median of 15.86, Nippon Shinyaku Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nippon Shinyaku Co's current EV-to-EBIT of 4.43 is 72.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nippon Shinyaku Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nippon Shinyaku Co's current EV-to-EBIT is 4.43, which is 73% below median its own 10-year median of 16.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nippon Shinyaku Co stock overvalued right now?
Based on GuruFocus' analysis, Nippon Shinyaku Co (TSE:4516) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,634.01, compared to a current price of 円3,640.00 — trading 21.5% below its estimated fair value. The current EV-to-EBIT is 4.43, which is 73% below median its 10-year median of 16.42 and 72.1% below the Drug Manufacturers industry median of 15.86. Nippon Shinyaku Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Nippon Shinyaku Co (TSE:4516), the current EV-to-EBIT is 4.43 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nippon Shinyaku Co (TSE:4516) Overvalued in 2026?
Based on GuruFocus' analysis, Nippon Shinyaku Co stock appears to be undervalued.
The current stock price of 円3,640.00 is trading 21.5% below its estimated GF Value™ of 円4,634.01.
GuruFocus considers Nippon Shinyaku Co to be Modestly Undervalued.
Key valuation signals for TSE:4516:
EV-to-EBIT: 4.43 (73% below median its 10-year median of 16.42)
GF Value™: 円4,634.01 vs. price of 円3,640.00 (21.5% below fair value)
Industry Position: 72.1% below the Drug Manufacturers median (#56 of 682)
No single metric tells the full story. See the TSE:4516 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nippon Shinyaku Co Ltd is engaged in the pharmaceuticals and functional food businesses. The Pharmaceuticals Business develops and sells treatments for urological disorders, blood cancer, rare and intractable diseases, and gynecological conditions. The Functional Food Business produces and sells health food ingredients, quality-stabilizing preservatives, protein preparations, and supplements. It generates the majority of its revenue from the Pharmaceuticals segment.
79GF Score
Get the complete analysis for TSE:4516
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4516 has been successfully added to your 
